Asterias Biotherapeutics (AST) Tops Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- BOJ eyeing September rate hike, faster pace of tightening, sources say
Asterias Biotherapeutics Reports Second Quarter Results and Highlights Progress of SCiSTAR Study Evaluating AST-OPC1 in Spinal Cord Injury Patients
August 15, 2016 4:01 PM EDTÂ
FREMONT, Calif., Aug. 15, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today reported financial results for the second quarter ended June 30, 2016 and recent highlights. The company continued to achieve notable clinical progress with AST-OPC1, its experimental treatment derived from pluripotent stem cells for spinal cord injury. Up to this point only patients with the most severe sensory and motor complete cervical spinal cord injuries have been enrolled in the SCiSTAR study, but... More
